 | • レポートコード：MRC2-11QY08114 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経障害治療薬のグローバル市場について調査・分析したレポートです。種類別（抗精神病薬、催眠薬・鎮静薬、鎮痛薬、抗凝固薬、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経障害治療薬の競争状況、市場シェア ・世界の神経障害治療薬市場：種類別市場規模 2015年-2020年（抗精神病薬、催眠薬・鎮静薬、鎮痛薬、抗凝固薬、その他） ・世界の神経障害治療薬市場：種類別市場規模予測 2021年-2026年（抗精神病薬、催眠薬・鎮静薬、鎮痛薬、抗凝固薬、その他） ・世界の神経障害治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック） ・世界の神経障害治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック） ・北米の神経障害治療薬市場分析：米国、カナダ ・ヨーロッパの神経障害治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経障害治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経障害治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経障害治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis AG、GlaxoSmithKline plc、Merck & Co.、Bayer AG、AstraZeneca、Boehringer Ingelheim GmbH、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Market Analysis and Insights: Global Neurological Disorder Drugs Market
The global Neurological Disorder Drugs market size is projected to reach US$ 20020 million by 2026, from US$ 19270 million in 2020, at a CAGR of 3.6%% during 2021-2026.
Global Neurological Disorder Drugs Scope and Market Size
Neurological Disorder Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neurological Disorder Drugs market is segmented into
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segment by Application, the Neurological Disorder Drugs market is segmented into
Hospital
Clinic
Regional and Country-level Analysis
The Neurological Disorder Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurological Disorder Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
Neurological Disorder Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurological Disorder Drugs business, the date to enter into the Neurological Disorder Drugs market, Neurological Disorder Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
…
1 Study Coverage
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market Segments
1.3 Key Neurological Disorder Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neurological Disorder Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurological Disorder Drugs Revenue 2015-2026
2.1.2 Global Neurological Disorder Drugs Sales 2015-2026
2.2 Global Neurological Disorder Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neurological Disorder Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neurological Disorder Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neurological Disorder Drugs Competitor Landscape by Players
3.1 Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Neurological Disorder Drugs Sales by Manufacturers (2015-2020)
3.1.2 Neurological Disorder Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Neurological Disorder Drugs Revenue by Manufacturers
3.2.1 Neurological Disorder Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2019
3.2.5 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neurological Disorder Drugs Price by Manufacturers
3.4 Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurological Disorder Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neurological Disorder Drugs Market Size by Type (2015-2020)
4.1.1 Global Neurological Disorder Drugs Sales by Type (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue by Type (2015-2020)
4.1.3 Neurological Disorder Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurological Disorder Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neurological Disorder Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurological Disorder Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neurological Disorder Drugs Market Size by Application (2015-2020)
5.1.1 Global Neurological Disorder Drugs Sales by Application (2015-2020)
5.1.2 Global Neurological Disorder Drugs Revenue by Application (2015-2020)
5.1.3 Neurological Disorder Drugs Price by Application (2015-2020)
5.2 Neurological Disorder Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurological Disorder Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neurological Disorder Drugs by Country
6.1.1 North America Neurological Disorder Drugs Sales by Country
6.1.2 North America Neurological Disorder Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neurological Disorder Drugs Market Facts & Figures by Type
6.3 North America Neurological Disorder Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Neurological Disorder Drugs by Country
7.1.1 Europe Neurological Disorder Drugs Sales by Country
7.1.2 Europe Neurological Disorder Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neurological Disorder Drugs Market Facts & Figures by Type
7.3 Europe Neurological Disorder Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neurological Disorder Drugs by Region
8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Region
8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Type
8.3 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neurological Disorder Drugs by Country
9.1.1 Latin America Neurological Disorder Drugs Sales by Country
9.1.2 Latin America Neurological Disorder Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neurological Disorder Drugs Market Facts & Figures by Type
9.3 Central & South America Neurological Disorder Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neurological Disorder Drugs by Country
10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Country
10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Description and Business Overview
11.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
11.2.5 GlaxoSmithKline plc Related Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Description and Business Overview
11.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
11.3.5 Merck & Co. Related Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Description and Business Overview
11.4.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer AG Neurological Disorder Drugs Products Offered
11.4.5 Bayer AG Related Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Description and Business Overview
11.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
11.5.5 AstraZeneca Related Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Corporation Information
11.6.2 Boehringer Ingelheim GmbH Description and Business Overview
11.6.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
11.6.5 Boehringer Ingelheim GmbH Related Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Corporation Information
11.7.2 Teva Pharmaceutical Description and Business Overview
11.7.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
11.7.5 Teva Pharmaceutical Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neurological Disorder Drugs Market Estimates and Projections by Region
12.1.1 Global Neurological Disorder Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Neurological Disorder Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.2.2 North America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neurological Disorder Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neurological Disorder Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurological Disorder Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Neurological Disorder Drugs Market Segments
Table 2. Ranking of Global Top Neurological Disorder Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neurological Disorder Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Antipsychotic
Table 5. Major Manufacturers of Hypnotic & Sedative
Table 6. Major Manufacturers of Analgesics
Table 7. Major Manufacturers of Anticoagulants
Table 8. Major Manufacturers of Others
Table 9. Global Neurological Disorder Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Neurological Disorder Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Neurological Disorder Drugs Sales by Regions 2015-2020 (K Units)
Table 12. Global Neurological Disorder Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Neurological Disorder Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Neurological Disorder Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Neurological Disorder Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Neurological Disorder Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurological Disorder Drugs as of 2019)
Table 18. Neurological Disorder Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Neurological Disorder Drugs Price (2015-2020) (USD/Unit)
Table 21. Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Neurological Disorder Drugs Product Type
Table 23. Date of International Manufacturers Enter into Neurological Disorder Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 26. Global Neurological Disorder Drugs Sales Share by Type (2015-2020)
Table 27. Global Neurological Disorder Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Neurological Disorder Drugs Revenue Share by Type (2015-2020)
Table 29. Neurological Disorder Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 31. Global Neurological Disorder Drugs Sales Share by Application (2015-2020)
Table 32. North America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 33. North America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 34. North America Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 36. North America Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 37. North America Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Table 38. North America Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 39. North America Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Table 40. Europe Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 41. Europe Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 42. Europe Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 44. Europe Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 45. Europe Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Table 46. Europe Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 47. Europe Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Neurological Disorder Drugs Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Neurological Disorder Drugs Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Table 56. Latin America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 57. Latin America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 60. Latin America Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 61. Latin America Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Table 62. Latin America Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 63. Latin America Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Table 72. Novartis AG Corporation Information
Table 73. Novartis AG Description and Major Businesses
Table 74. Novartis AG Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Novartis AG Product
Table 76. Novartis AG Recent Development
Table 77. GlaxoSmithKline plc Corporation Information
Table 78. GlaxoSmithKline plc Description and Major Businesses
Table 79. GlaxoSmithKline plc Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. GlaxoSmithKline plc Product
Table 81. GlaxoSmithKline plc Recent Development
Table 82. Merck & Co. Corporation Information
Table 83. Merck & Co. Description and Major Businesses
Table 84. Merck & Co. Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Merck & Co. Product
Table 86. Merck & Co. Recent Development
Table 87. Bayer AG Corporation Information
Table 88. Bayer AG Description and Major Businesses
Table 89. Bayer AG Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Bayer AG Product
Table 91. Bayer AG Recent Development
Table 92. AstraZeneca Corporation Information
Table 93. AstraZeneca Description and Major Businesses
Table 94. AstraZeneca Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. AstraZeneca Product
Table 96. AstraZeneca Recent Development
Table 97. Boehringer Ingelheim GmbH Corporation Information
Table 98. Boehringer Ingelheim GmbH Description and Major Businesses
Table 99. Boehringer Ingelheim GmbH Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Boehringer Ingelheim GmbH Product
Table 101. Boehringer Ingelheim GmbH Recent Development
Table 102. Teva Pharmaceutical Corporation Information
Table 103. Teva Pharmaceutical Description and Major Businesses
Table 104. Teva Pharmaceutical Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Teva Pharmaceutical Product
Table 106. Teva Pharmaceutical Recent Development
Table 107. Global Neurological Disorder Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 108. Global Neurological Disorder Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 109. Global Neurological Disorder Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 110. Global Neurological Disorder Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 111. North America: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 112. North America: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Europe: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 114. Europe: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Asia Pacific: Neurological Disorder Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 116. Asia Pacific: Neurological Disorder Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 117. Latin America: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 118. Latin America: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Middle East and Africa: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 120. Middle East and Africa: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 122. Key Challenges
Table 123. Market Risks
Table 124. Main Points Interviewed from Key Neurological Disorder Drugs Players
Table 125. Neurological Disorder Drugs Customers List
Table 126. Neurological Disorder Drugs Distributors List
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurological Disorder Drugs Product Picture
Figure 2. Global Neurological Disorder Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Antipsychotic Product Picture
Figure 4. Hypnotic & Sedative Product Picture
Figure 5. Analgesics Product Picture
Figure 6. Anticoagulants Product Picture
Figure 7. Others Product Picture
Figure 8. Global Neurological Disorder Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Neurological Disorder Drugs Report Years Considered
Figure 12. Global Neurological Disorder Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Neurological Disorder Drugs Sales 2015-2026 (K Units)
Figure 14. Global Neurological Disorder Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Neurological Disorder Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Neurological Disorder Drugs Sales Market Share by Region in 2019
Figure 17. Global Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Neurological Disorder Drugs Revenue Market Share by Region in 2019
Figure 19. Global Neurological Disorder Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2019
Figure 21. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Neurological Disorder Drugs Sales Market Share by Type in 2019
Figure 24. Global Neurological Disorder Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Neurological Disorder Drugs Revenue Market Share by Type in 2019
Figure 26. Global Neurological Disorder Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Neurological Disorder Drugs Sales Market Share by Application in 2019
Figure 29. Global Neurological Disorder Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Neurological Disorder Drugs Revenue Market Share by Application in 2019
Figure 31. North America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 34. North America Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Neurological Disorder Drugs Market Share by Type in 2019
Figure 40. North America Neurological Disorder Drugs Market Share by Application in 2019
Figure 41. Europe Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 44. Europe Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Neurological Disorder Drugs Market Share by Type in 2019
Figure 56. Europe Neurological Disorder Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region in 2019
Figure 61. China Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Neurological Disorder Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Neurological Disorder Drugs Market Share by Application in 2019
Figure 85. Latin America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Neurological Disorder Drugs Market Share by Type in 2019
Figure 96. Latin America Neurological Disorder Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Neurological Disorder Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Neurological Disorder Drugs Market Share by Application in 2019
Figure 109. North America Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
糖尿病性神経障害治療薬の世界市場（～2026年） A drug used to treat mental illness caused by diabetes Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CA…- 注意欠陥多動性障害（ADHD）薬の世界市場（～2026年） Market Analysis and Insights: Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Attenti…
- 認知症・運動障害治療の世界市場（～2026年） Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality change…
- 双極性障害治療薬の世界市場（～2026年） Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics. Rise in prevalence of bipolar disorder, high…
- 脂質異常症治療の世界市場（～2026年） Lipid disorder means the people high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides,. Several biopharma companies are focusing on developing effective solutions for treating lipid disorders. Companies involved in lipid disorder treatment market include Teva Phar…